To search for product information for reagents, ancillaries and bulks please visit your local Catalog for Healthcare Professionals in eLabDoc, an eService within dialog.roche.com.
Predictive IHC assay
VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying NSCLC patients eligible for treatment with TECENTRIQ®.
VENTANA PD-L1 (SP263) Assay expands immunotherapy options for NSCLC patients through equipping pathologists by:
VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemistry assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the programmed death ligand-1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue specimens by light microscopy. The VENTANA PD-L1 (SP263) Assay is used with the OptiView DAB IHC Detection Kit for staining on the BenchMark ULTRA instrument.
NSCLC:
PD-L1 protein expression in ≥ 1% TC in NSCLC tissue is indicated as an aid in identifying NSCLC patients for treatment with Tecentriq (atezolizumab). *
Table 1. Therapy and associated indication.
View Full TableTable 1. Therapy and associated indication.
Indication for use | Therapy | PD-L1 Expression |
NSCLC | TECENTRIQ® | ≥1% TC |
*Please refer to the VENTANA PD-L1 (SP263) Assay method sheet for the full intended use statement and approved therapeutic labeling.